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UGT1A1 is a major locus inﬂuencing bilirubin levels
in African Americans
Guanjie Chen*,1, Edward Ramos1, Adebowale Adeyemo1, Daniel Shriner1, Jie Zhou1, Ayo P Doumatey1,
Hanxia Huang1, Michael R Erdos2, Norman P Gerry3, Alan Herbert4, Amy R Bentley1, Huichun Xu1,
Bashira A Charles1, Michael F Christman3 and Charles N Rotimi1
Total serum bilirubin is associated with several clinical outcomes, including cardiovascular disease, diabetes and drug
metabolism. We conducted a genome-wide association study in 619 healthy unrelated African Americans in an attempt to
replicate reported ﬁndings in Europeans and Asians and to identify novel loci inﬂuencing total serum bilirubin levels. We
analyzed a dense panel of over two million genotyped and imputed SNPs in additive genetic models adjusting for age, sex,
and the ﬁrst two signiﬁcant principal components from the sample covariance matrix of genotypes. Thirty-nine SNPs spanning
a 78kb region within the UGT1A1 displayed P-values o5 10 8. The lowest P-value was 1.7 10 22 for SNP rs887829.
None of SNPs in the UGT1A1 remained statistically signiﬁcant in conditional association analyses that adjusted for rs887829.
In addition, SNP rs10929302 located in phenobarbital response enhancer module was signiﬁcantly associated with bilirubin
level with a P-value of 1.37 10 11; this enhancer module is believed to have a critical role in phenobarbital treatment of
hyperbilirubinemia. Interestingly, the lead SNP, rs887829, is in strong linkage disequilibrium (LD) (r2Z0.74) with
rs10929302. Taking advantage of the lower LD and shorter haplotypes in African-ancestry populations, we identiﬁed rs887829
as a more reﬁned proxy for the causative variant inﬂuencing bilirubin levels. Also, we replicated the reported association
between variants in SEMA3C and bilirubin levels. In summary, UGT1A1 is a major locus inﬂuencing bilirubin levels and
the results of this study promise to contribute to understanding of the etiology and treatment of hyperbilirubinaemia in
African-ancestry populations.
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INTRODUCTION
Bilirubin is an end product of heme metabolism. Heme, a component
of hemoglobin in red blood cells, is broken down by heme oxygenase
resulting in bilirubin.1,2 Glucuronidation by UDP-glycosyltransferase
in hepatocytes3 is an important step in facilitating the excretion
of bilirubin into bile.4 A very high level of bilirubin, especially in
children, is neurotoxic. In contrast and because of its potent anti-
oxidant effect, moderately elevated bilirubin has been shown to be
protective against several adult oxidative stress-mediated diseases
including diabetes mellitus, diabetic nephropathy, cancer and cardio-
vascular disease.5–9 Moderately higher levels of bilirubin within the
normal range have been associated with reduced risk of respiratory
disease and all cause mortality.10 Additionally, high serum bilirubin is
apparently beneﬁcial for survival in the elderly population.11
Previously, linkage studies identiﬁed a serum bilirubin QTL on
chromosome 2q (containing the UDP glycosyltransferase 1 family,
UGT1A) in European-ancestry populations, a ﬁnding that was repli-
cated in American Indians.12–14 Recently, multiple genome-wide
association studies (GWAS) identiﬁed variants in UGT1A to be
associated with serum bilirubin levels in European- and East-Asian-
ancestry populations.15–17 The aim of the present study is to investigate
if these ﬁndings extend to African-ancestry populations, and to identify
novel loci by conducting a GWAS and replication study of serum
bilirubin in apparently healthy unrelated African Americans. Multiple
studies have reported that African-ancestry populations have lower
b i l i r u b i nl e v e l sc o m p a r e dw i t ho t h e ra n c e s t r a lg r o u p s . 18,19 Understand-
ing the genetic and non-genetic basis of circulating levels of bilirubin is
particularly important in populations of African ancestry given the
reported higher prevalence of low bilirubin related health conditions
(eg, diabetes, the heart and kidney diseases) in African Americans.
MATERIALS AND METHODS
Ethics statement
Ethical approval for the Howard University Family Study (HUFS) was obtained
from the Howard University IRB and written informed consent was obtained
from each participant.
Study sample
The HUFS is a population-based family study of African Americans in the
Washington, D.C. metropolitan area.20 The major objective of the HUFSwas to
enroll and examine a randomly ascertained sample of African American
families (ie, pedigree data collected), along with a set of unrelated individuals
(no pedigree data collected), from the Washington, D.C. metropolitan area for
the study of the genetic and environmental bases of common complex diseases
including hypertension, obesity, diabetes and associated phenotypes. In order
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families were not ascertained based on any phenotypes. To estimate heritability
of serum bilirubin, we used 1314 individuals within 328 pedigrees from HUFS.
Heritability was estimated using SOLAR.21 For the GWAS, we included the
subset of apparently healthy individuals (deﬁned as no type 2 diabetes, no
hypertension and no other major morbidity) with bilirubin measurements and
Affymetrix 6.0 (Santa Clara, CA, USA) SNP genotype data. The 619 individuals
that met these criteria comprised 330 subjects enrolled as individuals and 289
unrelated subjects from families (1 randomly selected from related persons in
each pedigree).
Serum total bilirubin measurement
Total bilirubin was measured on a Cobas Integra 400 Plus (Roche Diagnostics,
Indianapolis, IN, USA) using the Diazo method. Brieﬂy, this method is a
colorimetric method based on the reaction between bilirubin and diazotized
sulfanilic acid solution to produce a complex known as azobilirubin whose
maximum absorbance is pH dependant; to preserve the pH of the reaction an
oxalic acid/ sulfanilic acid buffer is used. The color intensity of the reaction is
proportional to the concentration of total bilirubin present in the sample and is
determined by the increase in absorbance at 552nm. The minimum detection
level for this assay is 0.099mg/dl. The reproducibility of the assay measured by
the coefﬁcient of variation between and within assays is between 0.45 and 0.8%.
Serum total bilirubin is reported in mg/dl.
Genotyping
DNA was extracted using buffy coat samples following the manufacturer’s
instructions using a Gentra PUREGENE DNA Isolation Kit (QIAGEN,
Valencia, CA, USA). After sample processing, genome-wide genotyping was
performed using the Affymetrix Genome Wide Human SNP Array 6.0.22
Genotypes were called using Birdseed, version 2.22 All samples passed a sample
success rate of 95%. SNPs were excluded if they had a success rate of o95%
(41885 SNPs excluded), a minor allele frequency (MAF) r0.01 (19154 SNPs
excluded), or had a P-value for the Hardy-Weinberg test of equilibrium o10 3
(6317 SNPs excluded). The current analysis focused on the 808465 autosomal
SNPs that passed these ﬁlters. The sample genotyping rate for this set of SNPs
in these individuals was 99.5%. The concordance of blind duplicates was
99.74%. In addition, imputation was performed as previously reported.23
Brieﬂy, we successfully imputed 1506100 autosomal SNPs using the YRI
reference panel and an additional 52291 SNPs using the CEU reference panel,
for a total of 2366856 experimentally determined and imputed SNPs.
Check for population stratiﬁcation
EIGENSTRAT24 was used to detect and correct for population stratiﬁcation.
This method is based on principal components analysis and the resulting
correction is speciﬁc to a candidate marker’s variation in frequency across
ancestral populations, minimizing spurious associations whereas maximizing
power to detect true associations. The ﬁrst two principal components were
signiﬁcant and were included as covariates in the regression analysis.
Association and replication analyses
All association and conditional association testing was performed using
PLINK.25 Serum bilirubin levels were natural log transformed to follow a
normal distribution. Association between an autosomal marker and serum
bilirubin was assessed using linear regression assuming an additive genetic
effect model with adjustments for age, sex and ﬁrst two principal components
from EIGENSTRAT. We estimated the genomic inﬂation factor (lGC)b a s e do n
the median chi-squared test of all study participants.26 Conditional analyses to
examine speciﬁc SNP associations were performed using PLINK by specifying
the associated SNP as a covariate along with the previously mentioned
covariates in the linear regression model.
We attempted to replicate published GWAS of serum bilirubin15–17 in the
HUFS samples in two stages: direct (ie, same SNPs as reported) and local
(ie, SNPs in reference ancestry linkage disequilibrium (LD) with reported
SNPs) replication as previously reported.27 Of the 13 reported SNPs, we were
able to directly test 7 in this study; the remaining 6 were either not present on
the Affymetrix 6.0 chip, were not successfully imputed or failed our quality
control ﬁlters. Local replication was performed for SNPs not directly replicated.
The SNPs in LD at an r2Z0.3 with discovery variants were queried. HapMap
CEU reference data for European-ancestry populations and the HapMap CHB
data for the East Asian-ancestry populations were used in the local replication
analysis. To adequately account for multiple testing, we estimated the effective
degrees of freedom for the spectrally decomposed covariance matrix for the block
of SNPs using the HUFS genotyped SNP data as previously described.27,28
Power calculations were done using the Quanto software package.29 We used
a mean (SD) of serum bilirubin¼0.58 (0.31) mg/dl, MAF values obtained from
HUFS genotype dataset, and assumed an additive genetic model with
a¼5 10 8 in two tail tests to calculate study power.
RESULTS
Clinical characteristics for the 619 participants included in this study
are presented in Table 1. Consistent with the national data from
NHANES III, male participants had signiﬁcantly higher levels of
bilirubin than the females.30 In contrast, female participants were
heavier and had higher levels of insulin, and male participants had
higher systolic blood pressure, fasting glucose and alanine amino
transferase levels. Only a small proportion (3.8%) of the HUFS
participants had elevated (ie, 41.3mg/dl) serum total bilirubin level.
The heritability (h 2) of serum total bilirubin in HUFS is 0.42 (SE
0.064) with a P-value of 6.63 10 13.
The distribution of genome-wide association P-values for total
serum bilirubin is displayed in a Manhattan plot (Supplementary
Figure 1) and in a quantile-quantile plot (Supplementary Figure 2).
The value of genomic control inﬂation factor (lGC) was 1.008, which
indicated that inﬂation of association test statistics because of popula-
tion stratiﬁcation was negligible. Out of the 100 top scoring SNPs 39
(Supplementary Table S1) were located within a 78kb region in the
UGT1A1 gene on 2q37; all 39 SNPs displayed P-values lower than the
predetermined genome wide threshold of 5 10 8 (Supplementary
Figure 3 and Supplementary Table S2). The lowest P-value corres-
ponded to rs887829 (1.97 10 22). After conditioning on the most
signiﬁcant SNP (rs887829), none of the remaining 38 SNP in the
UGT1A1 gene maintained genome-wide signiﬁcance (Supplementary
Table S2). This ﬁnding is consistent with the observation that the
38 SNPs are in moderate to strong LD with rs887829 (r2 ranged from
0.28 to 1.0 in this study). Of note, previous studies identiﬁed rs887829
as a modiﬁer of bilirubin levels with each copy of the Tallele resulting
in an average increase of 1.77mg/dl in serum bilirubin in Europeans;17,31
the corresponding estimate of effect size in this study of African
Americans is 1.25mg/dl per copy of the T allele. SNP rs887829
explained 12.4% of the variance in serum total bilirubin in this
study of African Americans.
Table 1 Clinical characteristics of African American participants
included in this study
Male Female P-values
N (%) 251 (40.55%) 368 (59.45%)
Age (years) 40.74±11.54 41.19±11.83 0.641649
Height (cm) 176.44±6.99 163.76±7.18 1.75E-78
Body mass index (Kg/m2)2 7 . 3 5 ±6.14 30.64±8.37 2.76E-08
Systolic B.P. (mmHg) 118.41±10.48 116.51±10.77 0.028991
Diastolic B.P. (mmHg) 75.26±8.69 74.31±7.5 0.160415
Fasting glucose (mg/dl) 85.29±11.08 82.99±9.14 0.006826
Insulin (uU/ml) 9.18±8.65 11.24±18.04 0.061149
Bilirubin (mg/dl) 0.7±0.34 0.5±0.28 7.01E-14
Alanine AMINO Transferase (U/L) 15.43±18.48 10.35±11.11 0.000129
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4.78 10 156)r e p o r t e di nt h eK o r e a nG W A S . 15 This SNP was also
reported in the GWAS conducted in European-ancestry popula-
tions;16,17 however, SNP rs11891311 is in moderate LD (r240.66)
with the top scoring UGT1A1 SNP (rs887829) in European-
ancestry populations (Table 2). This is in sharp contrast to the weaker
LD (0.26 in HapMap YRI and 0.31 in HUFS) observed between these
SNPs in African-ancestry populations (Supplementary Table S3,
Supplementary Figure 4). Despite the weaker LD in our African-
ancestry population, we were able to directly replicate all three SNPs
in African Americans, perhaps indicating the robustness of previous
ﬁndings.
As described in the materials and methods section, we also con-
ducted local replication analyses of SNPs in LD (r2Z0.3) with the
reported SNPs in European- and East-Asian-ancestry populations.
This approach was implemented when the reported SNP was not
available because it failed one or more of our quality-control ﬁlters or
was not genotyped or successfully imputed. This approach yielded
additional signiﬁcant associations after Bonferroni correction for
multiple testing. For example, SNP rs4148323 in the UGT1A1 gene
with a MAF of 0.211 in East Asians was successfully replicated by SNPs
in LD with it using the local approach despite been monomorphic in
CEU, YRI and African Americans (Table 2, Figure 1). Notably, we
successfully replicated all four previously reported UGT1A1 variants
from GWAS of serum bilirubin in European- or East-Asian-ancestry
populations using either the direct or local replication approaches in
our African American study (Table 2).
In addition, we replicated reported association between variants
in the semaphorin 3C (SEMA3C) gene and bilirubin levels.16
The discovery SNP (rs4236644) located in the SEMA3C gene was
locally replicated by two LD based SNPs (rs1358503 and rs10251680,
P-values 0.0461 and 0.0447, respectively, Figure 2). Each SNP
explained B1% of the variance in serum bilirubin levels in this
study of African Americans.
DISCUSSION
The present study has conﬁrmed the important role of the UGT1A1
gene in serum total bilirubin levels in an African-ancestry population.
In this sample of African Americans, the most signiﬁcantly associated
variant (rs887829) is located in the core promoter region of the
UGT1A1 gene. Speciﬁcally, rs887829 is 211bp upstream of the short
thymine adenine (TA)n repeat sequence covering the TATA box of
the UGT1A1 gene. The same SNP was previously reported to be
associated with bilirubin levels in populations of East Asians and
Europeans.15–17 Of note, we also replicated the most signiﬁcant
SNP (rs11891311) reported in East Asians and Europeans.15–17
This SNP is 28kb upstream from and is in moderate LD
(r 2¼0.31) with rs887829 in African Americans. However, the two
SNPs show stronger LD (r2¼0.73) in East Asians and Europeans
(r2¼0.66) as estimated using the HapMap CHB and CEU reference
data (Supplementary Table S3 and Supplementary Figure 4). These
differences in LD and greater association of rs887829 in HUFS
(Table 2) taken together with its functional proximity (ie, near
promoter elements) support the likelihood that rs887829 is a more
reﬁned proxy for the causative candidate SNP inﬂuencing serum
total bilirubin levels. Our ability to reﬁne this GWAS signal is
because of the lower LD and shorter haplotypes present in
African-ancestry populations compared with European- and Asian-
ancestry populations; We note that we have successfully reﬁned
GWAS signals for fasting plasma glucose and serum uric acid using
African ancestry samples in previous studies.27,32
Interestingly, rs887829 is in strong LD (r2Z0.74) with rs10929302,
which was associated with serum total bilirubin with a P-value of
1.37 10 11 in the present study. SNP rs10929302 is located in the
phenobarbital response enhancer module and known to be associated
with irinotecan response.33 This implies that this small (B3kb region)
UGT1A1 region is pleiotropic, containing variants that inﬂuence:
(1) serum bilirubin levels, (2) phenobarbital induction of UGT1A1
expression and (3) irinotecan response.
Table 2 Replication of SNPs reported to be associated with serum bilirubin in Europeans and East Asians in our sample of African Americans
Reported
studies
HUFS
Direct replication LD-based replication
Population SNP Chr Position(bp) Genes MAF Location P-value Allelic Freq. P-values b (95%CI) # of SNPsa P valueb D.F.
Europeans17 rs887829 2 234333309 UGT1A1 0.30  311kb 1E-69 T (0.45) 1.97E-22 0.226 (0.183,0.270) 96 (81) 8.35E-22 2.73
rs11891311 2 234304049 UGT1A1 0.23  30kb 1E-25 G (0.41) 2.12E-05  0.104 ( 0.151,-0.056) 21 (21) 3.49E-22 1.77
rs2117032 12 20965389 SLCO1B3 0.46 4kb 3E-14 T (0.14) 7.857E-1  0.010 ( 0.08,0.061) 0 (0)
Europeans16 rs6742078 2 234337378 UGT1A1 0.32 Intron 1 5E-324 T (0.43) 8.23E-18 0.203 (0.158,0.248) 96 (81) 5.38E-22 2.73
rs887829 2 234333309 UGT1A1 0.32  311kb 5E-324 T (0.45) 1.97E-22 0.226 (0.183,0.270) 32 (29) 4.51E-22 2.29
rs11891311 2 234304049 UGT1A1 0.35  30kb 1E-235 G (0.41) 2.12E-05  0.104 ( 0.151, 0.056) 21 (21) 3.49E-22 1.77
rs4149056 12 21222816 SLCO1B1 0.15 Exon 7E-13 N/A N/A N/A 1 (0) 1.0 4.07
rs16928809 11 2893528 SLC22A18 0.10 Intron 1 1E-7 N/A N/A N/A 10 (0) 1.0 1.52
rs12714207 2 88096908 KRCC1 0.33 10kb 5E-7 C (0.47) 5.747E-1  0.014 ( 0.063,0.035) 3 (0) 1.0 1.62
rs12206204 6 26224961 HIST1H2BC 0.10  6kb 8E-7 N/A N/A N/A 0 (0) N/A N/A
rs1986655 4 126212952 0.15 Intergenic 2E-6 N/A N/A N/A 17 (0) 1.27E-1 2.75
rs4236644 7 80437293 SEMA3C 0.27  50kb 2E-6 N/A N/A N/A 6 (2) 4.47E-2 1.66
rs4773330 13 110616833 ARHGEF7 0.12 Intron 8 8E-6 A (0.18) 5.768E-1 0.017 ( 0.043,0.077) 46 (0) 3.447E-1 4.38
Korean15 rs11891311 2 234304049 UGT1A1 0.12  30kb 4.78E-156 G (0.41) 2.12E-05  0.104 ( 0.151, 0.056) 21 (21) 3.49E-22 1.77
rs887829 2 234333309 UGT1A1 0.12  311kb 5.37E-148 T (0.45) 1.97E-22 0.226 (0.183,0.270) 32 (29) 4.51E-22 2.29
rs6742078 2 234337378 UGT1A1 0.12 Intron 1 7.19E-148 T (0.43) 8.23E-18 0.203 (0.158,0.248) 32 (29) 4.53E-22 2.30
rs4148323 2 234333883 UGT1A1 0.19 Exon 1 5.07E-82 Mono.B N/A N/A 61 (52) 4.32E-22 2.19
rs2417940 12 20909142 SLCO1B3 0.21 Intron 7 2.42E-17 T (0.45) 2.329E-1 0.028 ( 0.018,0.074) 69 (0) N/A N/A
aNumber of SNPs in LD (r2Z0.3) with reported SNP in the reference sample. The number of SNPs in LD (r2Z0.3) with the reported SNP that showed association with serum bilirubin in HUFS
(Po0.05) are in parentheses.
bThe lowest Bonferroni-corrected P value (based on degrees of freedom, d.f.) within the 500kb query window.
Mono. B: Monomorphic in CEU, YRI, and HUFS.
N/A: SNPs not available in the HUFS genotype & imputation data set.
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(UGT) enzymes are essential to the proper metabolism of a number
of exogenous and endogenous compounds. The UGT1 family includes
UGT1A1, which has a critical role in the detoxiﬁcation of neurotoxic
bilirubin. Reduced UGT1A1 activity is associated with unconjugated
hyperbilirubinemia4 and loss of function has been observed in rare
inherited disorders (eg, Gilbert’s syndrome and Crigler–Najjar
syndrome). Recently, Horsfall et al19 reported that variation in the
short (TA)n repeat sequence in the UGT1A1 gene promoter is
associated with hyperbilirubinaemia.
There is also considerable continental and ethnic variation in the
distribution of the (TA)n repeat in the UGT1A1 gene.19,34 For
example, there are more (TA)n alleles in African populations com-
pared with European-ancestry populations. Alleles (TA)5,( T A ) 6,( T A ) 7
and (TA)8 have all been observed in most African populations studied
to date; in contrast, alleles (TA)5 and (TA)8 have not been observed in
Europeans.19,34 Also, large difference in allele frequency has been
observed across African ethnic groups. The low afﬁnity alleles (TA)7
and (TA)8 are highly prevalent in African populations around the
equator.19
Our study emphasizes the importance of conducting GWAS in
populations with ancestry from different parts of the world. For
example, rs4148323 in UGT1A1 was reported in East Asians15 with
a P-value of 1.22 10 82. In European (CEU), West African (YRI) and
African American (HUFS) samples, this variant is monomorphic
compared with a MAF of 0.211 in East Asian (CHB and JPT) HapMap
data. However, we were able to replicate this ﬁnding by querying a
500kb-window centered on rs4148323 and performing association
analysis on all 61 SNPs in LD using a cutoff r2Z0.3.
GWAS of serum bilirubin in European-ancestry populations also
reported signiﬁcant association with SNP rs4236644 located in the
SEMA3C gene; this gene has been linked to increased expression of
severe steatotic livers.35 After Bonferroni correction, local replication
using rs4236644 as the query SNP, we observed signiﬁcant association
between SNPs (rs1358503 and rs10251680) and bilirubin level
(P-values¼0.0461 and 0.0447, respectively). In African-ancestry popu-
lations, the locally replicated SNPs have higher r2 values with the
discovery SNP when compared with European ancestry (Figure 3).
Using HapMap CHB data or JPT data, LD is even weaker, which may
explain why this SNP was not observed in the GWAS of bilirubin in
Koreans.
Despite the small sample size relative to other GWAS, this study had
98 and 94% power, respectively, to replicate the robust effect sizes
(1.25mg/dl and 1.23mg/dl, respectively), reported for the two top
scoring SNPs (rs887829 and rs6742078) in the UGT1A1gene among
European and East Asian populations (Table 2).15–17 However, it had
lower power (21%) for a third SNP, rs11891311, reported in an East
Asian study.15 Estimated effective sizes in this study of African
Americans are 1.25mg/dl, 1.23mg/dl and 1.11mg/dl, respectively,
for rs887829, rs6742078 and rs11891311, compared with 1.77mg/dl,
1.26mg/dl and 1.2mg/dl reported in European and East Asian
populations.15–17
In summary, we showed that UGT1A1 is a major locus inﬂuencing
serum total bilirubin levels in African Americans. Our ﬁndings may
also contribute to the understanding of the etiology and the treat-
ment of hyperbilirubinaemia in African-ancestry populations. Taking
advantage of the lower LD and shorter haplotypes present in African-
ancestry populations, we reﬁned previously reported association of
Figure 2 Corrected P-values and LD in this sample of African Americans
(HUFS) for rs4236644 located in the promoter region of the SEMA3C gene.
The red arrow points to the position of SNP rs4236644 in Europeans. The
two red dots are for SNPs rs1358503 and rs10251660 that locally
replicated the original discovery SNP (rs4236644) in individuals of
European ancestry. SNPs rs1358503 and rs10251660 are in moderate LD
(r2¼0.33) with rs4236644 in Europeans.
Figure 1 Corrected P-values and LD in this sample of African Americans
(HUFS) for rs4148323 located in an intronic region of the UGT1A1 gene.
The red arrow points to the position of the original discovery SNP
(rs4148323) in individuals of East Asian ancestry. The two red dots are for
SNPs rs887829 and rs6742078 that locally replicated the original
discovery SNP (rs4148323) in individuals of East Asian ancestry. Also,
SNPs rs887829 and rs6742078 were among the top signiﬁcant ﬁndings in
East Asians and Europeans.
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using ethnically diverse populations for replication studies.
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